Private Wealth Asset Management LLC bought a new position in shares of Incyte Corporation (NASDAQ:INCY – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 13,375 shares of the biopharmaceutical company’s stock, valued at approximately $1,600,000.
Other institutional investors also recently bought and sold shares of the company. Private Advisor Group LLC lifted its position in shares of Incyte by 109.4% in the third quarter. Private Advisor Group LLC now owns 4,296 shares of the biopharmaceutical company’s stock worth $521,000 after buying an additional 2,244 shares during the last quarter. Focus Advisor Solutions LLC raised its holdings in Incyte by 54.1% in the 3rd quarter. Focus Advisor Solutions LLC now owns 44,249 shares of the biopharmaceutical company’s stock worth $5,370,000 after acquiring an additional 15,527 shares during the period. Independent Advisor Alliance raised its holdings in Incyte by 30.4% in the 3rd quarter. Independent Advisor Alliance now owns 7,185 shares of the biopharmaceutical company’s stock worth $872,000 after acquiring an additional 1,673 shares during the period. Meeder Asset Management Inc. lifted its position in Incyte by 518.5% during the 3rd quarter. Meeder Asset Management Inc. now owns 334 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 280 shares during the last quarter. Finally, Composition Wealth LLC acquired a new position in Incyte during the 3rd quarter worth $212,000. 96.97% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Several brokerages recently weighed in on INCY. Canaccord Genuity Group assumed coverage on Incyte in a research note on Thursday, August 20th. They set a “buy” rating and a $152.00 target price for the company. Jefferies Financial Group set a $115.00 price objective on shares of Incyte and gave the stock a “hold” rating in a report on Tuesday. Truist Financial raised their price objective on Incyte from $105.00 to $115.00 and gave the stock a “hold” rating in a research report on Wednesday, October 14th. BMO Capital Markets reiterated a “market perform” rating on shares of Incyte in a research report on Tuesday, October 27th. Finally, Raymond James Financial set a $152.00 price target on Incyte in a research report on Friday, October 16th. Eleven research analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $134.38.
Check Out Our Latest Stock Report on Incyte
Incyte Stock Performance
Shares of INCY opened at $114.63 on Friday. The stock has a fifty day moving average price of $118.49 and a two-hundred day moving average price of $109.37. Incyte Corporation has a 52-week low of $89.25 and a 52-week high of $132.60. The company has a market cap of $23.37 billion, a price-to-earnings ratio of 60.97, a PEG ratio of 4.38 and a beta of 0.78.
Incyte (NASDAQ:INCY – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($3.60) EPS for the quarter, topping analysts’ consensus estimates of ($3.93) by $0.33. The company had revenue of $1.56 billion for the quarter, compared to analyst estimates of $1.46 billion. Incyte had a return on equity of 7.92% and a net margin of 6.71%. The business’s revenue was up 14.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.26 earnings per share. As a group, research analysts predict that Incyte Corporation will post 2.29 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, insider Pablo Cagnoni sold 2,642 shares of the company’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $112.71, for a total transaction of $297,779.82. Following the transaction, the insider owned 183,200 shares in the company, valued at $20,648,472. This represents a 1.42% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Thomas Tray sold 610 shares of the company’s stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $118.96, for a total transaction of $72,565.60. Following the transaction, the insider owned 21,126 shares in the company, valued at approximately $2,513,148.96. This trade represents a 2.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 254,139 shares of company stock valued at $30,098,844. 16.20% of the stock is owned by corporate insiders.
Incyte Company Profile
Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.
Recommended Stories
- Five stocks we like better than Incyte
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY – Free Report).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.
